Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INHL - Inhale Therapeutics - Pulmonary Insulin! -- Ignore unavailable to you. Want to Upgrade?

To: dwc who wrote (178)	2/2/2001 10:23:17 AM
From: deeno	Read Replies (1) \| Respond to of 225

any personal insights? nhale Thera Sees 8 -9 Products In Clinical Tests In 2001 01/31 15:36 (DJ) Story 6785 (AVE, BGEN, INHL, LLY, PFE) By Beth Mantz Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Inhale Therapeutic Systems Inc. (INHL) expects to have eight or nine products in clinical testing during 2001, Chairman Robert Chess said at the U.S. Bancorp Piper Jaffray Healthcare Conference Wednesday. The addition of four to five new early-stage human tests to its current clinical programs further demonstrates Inhale Therapeutic's flexible platform for creating its own versions of current drugs. The ultimate success of these drugs could bring a portion of the $15 billion market of macromolecule drugs into Inhale Therapeutic's coffers. The company has developed several ways to form powder out of large-size molecules that are currently injected or swallowed. It has also created three devices that can deliver this powder so the medicine can be inhaled, channeled through the lungs and absorbed into the body. Such flexibility enables Inhale Therapeutic to target several disease areas and team up with certain drug makers to capture existing market share for current injectible and oral drugs, as well as to add those patients who are either not currently or insufficiently treated. Inhale Therapeutic could see its most advanced drug candidate, inhaled insulin, filed for marketing approval by its development and commercial partners Pfizer Inc. (PFE) and Aventis SA (AVE) this year. In addition, Inhale Therapeutic has partnered with Biogen Inc. (BGEN) to develop an inhaled version of multiple-sclerosis treatment Avonex. It also is working with Eli Lilly & Co. (LLY) to create an inhaled version of osteoporosis drug Forteo, and with Aventis Behring on an inhaled form of Alpha-1 for genetic emphysema. - By Beth Mantz, Dow Jones Newswires; 201 -938 -5287 (END) DOW JONES NEWS 01 -31 -01